Skip to content
10-Q

Quarterly Report

20/20 BIOLABS, INC. AIDX

0001213900-26-059542

← back to feed
Filed
May 20, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 19, 2026 10.61M sh
Shares Diluted Q1 2026 · Mar 31, 2026 7.66M sh
Shares Diluted Q1 2026 · Mar 31, 2025 4.82M sh
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$1.29M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$488.29K
Cash And Equivalents Q1 2026 · Mar 31, 2026 $4.22M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $1.03M
Stockholders Equity Q1 2026 · Mar 31, 2026 $2.55M
Stockholders Equity Q1 2026 · Dec 31, 2025 −$19.23K
Stockholders Equity Q1 2026 · Mar 31, 2025 $1.06M
Stockholders Equity Q1 2026 · Dec 31, 2024 $1.51M
Current Liabilities Q1 2026 · Mar 31, 2026 $2.58M
Current Liabilities Q1 2026 · Dec 31, 2025 $2.46M
Total Liabilities Q1 2026 · Mar 31, 2026 $3.05M
Total Liabilities Q1 2026 · Dec 31, 2025 $4.16M
Current Assets Q1 2026 · Mar 31, 2026 $4.7M
Current Assets Q1 2026 · Dec 31, 2025 $1.47M
Total Assets Q1 2026 · Mar 31, 2026 $5.8M
Total Assets Q1 2026 · Dec 31, 2025 $4.14M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.28
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.16
Eps Basic Q1 2026 · Mar 31, 2026 −$0.28
Eps Basic Q1 2026 · Mar 31, 2025 −$0.16
Sga Expense Q1 2026 · Mar 31, 2026 $1.35M
Sga Expense Q1 2026 · Mar 31, 2025 $801.14K
Rd Expense Q1 2026 · Mar 31, 2026 $153.48K
Rd Expense Q1 2026 · Mar 31, 2025 $136.83K
Net Income Q1 2026 · Mar 31, 2026 −$2.17M
Net Income Q1 2026 · Mar 31, 2025 −$764.58K
Operating Income Q1 2026 · Mar 31, 2026 −$1.44M
Operating Income Q1 2026 · Mar 31, 2025 −$772.18K
Gross Profit Q1 2026 · Mar 31, 2026 $62.88K
Gross Profit Q1 2026 · Mar 31, 2025 $165.8K
Cost Of Revenue Q1 2026 · Mar 31, 2026 $290.49K
Cost Of Revenue Q1 2026 · Mar 31, 2025 $388.03K
Revenue Q1 2026 · Mar 31, 2026 $353.38K
Revenue Q1 2026 · Mar 31, 2025 $553.82K